Publications by authors named "Arlen Wilcox"
Article Synopsis
- This study aimed to assess whether DMX-200, a chemokine receptor antagonist, combined with candesartan, could improve outcomes for hospitalized adults under 65 with moderate to severe COVID-19.
- Conducted in ten hospitals in India, the trial was double-blind and placebo-controlled but was terminated early due to challenges in recruitment, resulting in only 49 participants.
- Preliminary results showed both treatment groups had similar outcomes, with no significant differences in disease progression, ICU admissions, or length of hospital stays, indicating that the intervention may not have had a notable impact.
Objective: To determine whether disrupting the renin angiotensin system with angiotensin receptor blockers will improve clinical outcomes in people with covid-19.
Design: CLARITY was a pragmatic, adaptive, multicentre, phase 3, randomised controlled trial.
Setting: 17 hospital sites in India and Australia.
Background: SARS-CoV-2 binds to membrane-bound angiotensin-converting enzyme 2 (ACE2) which may result in downregulation of membrane-bound ACE2. ACE2 is a key regulator of the renin-angiotensin system (RAS) and is responsible for degrading angiotensin II and thereby counteracting its pro-inflammatory, pro-fibrotic effects mediated through the angiotensin II type 1 receptor (AT1R). As AT1R is directly blocked by angiotensin receptor blockers (ARBs), these agents may offer a safe, low-cost solution for reducing COVID-19 respiratory outcomes.
View Article and Find Full Text PDF